Ferrier I N (1999) Treatment of major depression: is improvement enough?J Clin Psychiatry60 (Suppl. 6): 10–14
2.
Judd L L, Akiskal H S, Paulus M P (1997) The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord45: 5–17
3.
Kennedy N, Paykel E S (2004) Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord80: 135–144
4.
Nierenberg A A, Wright E C (1999) Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry60 (Suppl. 22): 7–11
5.
Papakostas G I, Petersen T, Denninger J W, Tossani E, Pava J A, Alpert J E, Nierenberg A A, Fava M (2004) Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol24: 507–511
6.
Paykel E S, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med25: 1171–1180
7.
Rush A J, Trivedi M (1995) Treating depression to remission. Psychiatr Ann25: 704–710
8.
Thase M E, Entsuah A R, Rudolph R L (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry178: 234–241
9.
Thase M E, Haight B R, Richard N, Rockett C B, Mitton M, Modell J G, Vanmeter S, Harriett A E, Wang Y (2005) Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry66: 974–981
10.
Trivedi M H, Rush A J, Wisniewski S R, Nierenberg A, Warden D, Ritz L, Norquist G, Howland R H, McGrath P J, Shores-Wilson K, Biggs M M, Balasubramani G I, Fava M, STAR*D Study Team (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D implications for clinical research and practice. Am J Psychiatry163: 28–40
